Imetelstat Combination Therapy
A Phase 1 Study of GRN163L (Imetelstat) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia That is in Second or Greater Relapse or That is Refractory to Relapse Therapy; Myelodysplastic Syndrome or Juvenile Myelomonocytic Leukemia in First or Greater Relapse or is Refractory to Relapse Therapy
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 36 patients (estimated)
- Sponsors
- Children's Oncology Group
- Collaborators
- Geron Corporation, National Cancer Institute (NCI)
- Tags
- Telomerase Inhibitor
- Trial Type
- Treatment
- Last Update
- 4 weeks ago
- SparkCures ID
- 1964
- NCT Identifier
- NCT06247787
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.